Nyland JE, Raja-Khan NT, Bettermann K, et al. - Receipt of glucose-regulating medications, such as glucagon-like peptide-1 receptor (GLP-1R) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, or pioglitazone may associate with achievement of improved outcomes among COVID-19 patients with type 2 diabetes mellitus (T2DM).

• A multinational retrospective cohort study performed using the TriNetX COVID-19 Research Network of 56 large healthcare organizations.

• Significant reductions in hospital admissions were recorded in correlation with using GLP-1R agonists and/or pioglitazone (GLP-1R: 15.7% vs 23.5%; pioglitazone: 20.0% vs 28.2%).

• In addition, reductions in respiratory complications (15.3% vs 24.9%) and incidence of mortality (1.9% vs 3.3%) were observed in correlation with the use of GLP-1R agonists.

• There was a reduction in respiratory complications (24.0% vs 29.2%) with the use of DPP-4 inhibitors, and a decrease in mortality with continued use of DPP-4 inhibitors after hospitalization vs those who discontinued use (9% vs 19%).